Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients.